Menu
GWAS Study

Male-specific epistasis between WWC1 and TLN2 genes is associated with Alzheimer's disease.

Gusareva ES, Twizere JC, Sleegers K et al.

30201328 PubMed ID
GWAS Study Type
38582 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

GE
Gusareva ES
TJ
Twizere JC
SK
Sleegers K
DP
Dourlen P
AJ
Abisambra JF
MS
Meier S
CR
Cloyd R
WB
Weiss B
DB
Dermaut B
BK
Bessonov K
VD
van der Lee SJ
CM
Carrasquillo MM
KY
Katsumata Y
CM
Cherkaoui M
AB
Asselbergh B
IM
Ikram MA
MR
Mayeux R
FL
Farrer LA
HJ
Haines JL
PM
Pericak-Vance MA
SG
Schellenberg GD
SR
Sims R
WJ
Williams J
AP
Amouyel P
VD
van Duijn CM
EN
Ertekin-Taner N
VB
Van Broeckhoven C
DF
Dequiedt F
FD
Fardo DW
LJ
Lambert JC
VS
Van Steen K
Chapter II

Abstract

Summary of the research findings

Systematic epistasis analyses in multifactorial disorders are an important step to better characterize complex genetic risk structures. We conducted a hypothesis-free sex-stratified genome-wide screening for epistasis contributing to Alzheimer's disease (AD) susceptibility. We identified a statistical epistasis signal between the single nucleotide polymorphisms rs3733980 and rs7175766 that was associated with AD in males (genome-wide significant pBonferroni-corrected=0.0165). This signal pointed toward the genes WW and C2 domain containing 1, aka KIBRA; 5q34 and TLN2 (talin 2; 15q22.2). Gene-based meta-analysis in 3 independent consortium data sets confirmed the identified interaction: the most significant (pmeta-Bonferroni-corrected=9.02*10-3) was for the single nucleotide polymorphism pair rs1477307 and rs4077746. In functional studies, WW and C2 domain containing 1, aka KIBRA and TLN2 coexpressed in the temporal cortex brain tissue of AD subjects (β=0.17, 95% CI 0.04 to 0.30, p=0.01); modulated Tau toxicity in Drosophila eye experiments; colocalized in brain tissue cells, N2a neuroblastoma, and HeLa cell lines; and coimmunoprecipitated both in brain tissue and HEK293 cells. Our finding points toward new AD-related pathways and provides clues toward novel medical targets for the cure of AD.

788 male cases, 1,455 female cases, 2,362 male controls, 3,655 female controls

Chapter III

Study Statistics

Key metrics and study information

38582
Total Participants
GWAS
Study Type
Yes
Replicated
3,836 male cases, 6,244 female cases, 8,618 male controls, 11,624 female controls
Replication Participants
U.S., Germany, Netherlands, U.K., France
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.